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1. Introduction 
1.1 Current situation in the development of pharmaceuticals 
A typical testing scheme for a small-molecule therapeutics (outlined in Fig. 1) begins with a 
large number of compounds and high-throughput assays (Kramer et al., 2007). As the 
number of viable lead molecules is reduced, incrementally more predictive but lower 
throughput assays identify those leads with the most drug-like properties and optimal in 
vitro and in vivo efficacy. Confirmed hit compounds identified in high-throughput screens 
are evaluated for potency, selectivity, ADME (absorption, distribution, metabolism and 
excretion), physical and chemical properties, and activity in relevant animal models (Fig. 1). 
This testing paradigm typically delivers drug-like compounds that have promising 
pharmacokinetic parameters and efficacy in preclinical models within a 1–2-year cycle time. 
Compounds that successfully meet preclinical efficacy, ADME, pharmacokinetics and safety 
criteria are nominated as candidates for formal development. Historically, the move from 
discovery to development consisted of a discreet hand-off from the ‘discovery’ organization 
to the ‘development’ organization, and little preclinical safety assessment was performed on 
lead molecules beyond a few basic in vitro toxicity assays. As toxicity is a primary cause for 
compound attrition and long development (Kola & Landis, 2004), companies in the past 5–
10 years have increasingly integrated safety assessment principles into earlier phases of the 
drug discovery process.  
Also as shown in Fig.1, the costs of R & D for a drug in 2001 were of the order of US $802 
million (DiMasi et al., 2003); current estimates are closer to about US $900 million; 
Considerably more of these costs are incurred later in the pipeline, and most of the attrition 
occurs during full clinical development (Phases II and III). In the other literature, it has been 
estimated that the average cost associated with the discovery and preclinical evaluation of a 
single drug candidate were US $620 million (Rawlins, 2004).  
Kola and Landis researched the reason why compounds undergo attrition and how this has 
changed over time (Kola. & Landis, 2004). In 1991, adverse pharmacokinetic and 
bioavailability results were the most significant cause of attrition and accounted for ~40% of 
all attrition. However, in 2000 the major causes of attrition in the clinical trials were lack of 
efficacy (accounting for approximately 30% of failures) and safety (toxicology in preclinical 
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development and safety in clinical development accounting for a further approximately 
30%). As a result, many companies developing small-molecule therapeutics have adopted a 
strategy that includes the earlier incorporation of preclinical safety assessment before 
advancement into regulated preclinical studies.  
  
Preclinical development
GLP toxicology studies: General toxicity, Specific toxicity 
including genotoxicity, Safety pharmacology
High-throughput screening
High content analysis, 
IC50 determination, Hit triage
Hit to lead
Selectivity assays, in vitro efficacy assays,
Tier I ADME/physical chemistry assays
Lead optimization
In vivo efficacy assays (preclinical POC), 
Tier II ADME/physical chemistry assays
Candidate seeking
Second species PK, PK/PD modeling,
Salt-form selection, Crystal form assessment
Clinical development
Phase I: Safety and tolerability in healthy volunteers
Phase II: Safety and tolerability in patients, early clinical POP
Phase III: Definitive clinical POP
1,000
100
Dozen
1-3
1
$467 million
$335 million
Number of chemicals
Cost for R & D  
Fig. 1. A typical testing scheme in the development for a small-molecule therapeutics. 
PK/PD, pharmacokinetic/pharmacodynamic; POC, proof-of-concept; POP, proof-of-
principle. ADME; absorption, distribution, metabolism and excretion, GLP; good laboratory 
practice. 
1.2 Safety assessment of pharmaceutical candidates before administration to humans 
according to the regulatory guidance 
Currently, drug companies tend to perform a fairly standard package of nonclinical studies 
before commencing First-In-Man (FIM) clinical trial investigations with pharmaceuticals. 
The non-clinical safety study recommendations for the marketing approval of a 
pharmaceutical usually include single and repeated dose toxicity studies, reproduction 
toxicity studies, genotoxicity studies, and local tolerance studies. For drugs that have special 
cause for concern or are intended for a long duration of use, an assessment of carcinogenic 
potential must be included. Other non-clinical studies include pharmacology studies for 
safety assessment (safety pharmacology) and pharmacokinetic (ADME) studies. 
For the conventional, chemically-synthesized small molecules, such a package of studies is 
in agreement with international regulatory guidance as given by the International 
Conference on Harmonization (ICH M3-R2) (Table 1). The genotoxic potential has to be 
assessed comprehensively before administration to humans regardless for both chemically-
synthesized small molecules and biotechnology-derived pharmaceuticals. 
According to the current international guidelines on genotoxicity testing of pharmaceutical 
candidates (ICH S2A, S2B and M3), a standard battery of tests has to be performed. This 
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battery generally includes (i) an in vitro test for gene mutation in bacteria; (ii) an in vitro test 
in mammalian cells with cytogenetic evaluation of chromosomal damage and/or a test that 
detects gene mutations; (iii) an in vivo test for chromosomal damage using rodent 
hematopoietic cells. For compounds giving negative results in all 3 of the assays, the 
completion of this test battery is generally considered to provide a sufficient level of safety 
in demonstrating the absence of genotoxic activity. 
1.3 Recent achievement in the in vitro genotoxicity testing 
The most widely used in vitro genotoxicity test is the Ames test (Ames et al., 1975). The 
relatively simplicity and low cost of the test make it a valuable screening tool for mutagens. 
However, DNA is naked in the prokaryote and the form of DNA is different from that in 
eukaryote. Thus, the test using mammalian cell lines has been developed Chromosomal 
alterations are quite common in malignant neoplasm, as such the detection of chromosomal 
abnormalities by test chemicals is considered an excellent test for the assessment of 
carcinogenic potential. In mammalian cell lines, most of the test systems used the same lines 
as used in the genotoxicity test. 
An important discovery in the understanding of chemical carcinogenesis came from the 
investigation of the Millers who established that many carcinogens are not intrinsically 
carcinogenic, but require metabolic activation to be carcinogenic (Miller and Miller, 1947). 
They demonstrated that azo dyes covalently bind to proteins in liver, leading to the 
conclusion that carcinogens may bind to proteins that are critical for cell growth control 
(Miller and Miller, 1947). An additional investigation with other genotoxic carcinogens 
which requires metabolic activation confirmed that metabolism of the parent compound 
was necessary to produce a metabolite (activation) that was able to interact with DNA.  
In standard in vitro genotoxicity testing, an activation system is included with the purpose 
of generating electrophilic metabolites that can react with macromolecules including nucleic 
acids. To address the potential role of metabolism, the induced rat liver S9 has been adopted 
for in vitro genotoxicity tests as an exogenous activation system for detecting promutagens 
(Ames et al., 1973, Paolini, 1997). Its initial choice was logical; levels of several cytochrome 
P450 (CYP) enzymes are elevated after induction, in particular the CYP1A subfamily of 
enzymes (CYP1A1 and 1A2), which are efficient catalysts of the bioactivation of polycyclic 
aromatic hydrocarbons and azaarenes, aromatic amines and aflatoxins. These types of 
compounds were some of the first known and best understood mutagens and the Aroclor 
1254-induced rat S9 fraction effectively allowed for their identification as mutagens. Its 
choice was also logical in that it provided a reliable, robust and readily available 
bioactivation system at a time when human-derived systems were rare or unavailable. Also, 
a rodent system can be more easily standardized than an exogenous human derived system 
that normally would rely on human tissue samples, which are subject to significant 
biological variation. 
1.4 Problems in the use of rat liver S9 fraction as a metabolic activation system in 
vitro genotoxicity testing 
As mentioned in the above sections, the initial choice of rat liver S9 fraction as a metabolic 
activation system in the in vitro genotoxicity testing was logical. However, it can be 
questioned if the standard Aroclor-induced rat liver S-9 fraction represents an appropriate 
surrogate for the metabolic capabilities of humans for the following reasons (Ku et al., 2007; 
Obach and Dobo, 2008). First, it is now known that the rat and human CYP enzymes can  
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Menu  Purpose  
General Toxicity  
Acute toxicity  To identify doses causing no adverse effect and doses 
causing major (life-threatening) toxicity.  
(Sub) Chronic toxicity  To characterize the toxicological profile of a chemical 
following repeated administration.  
Specific Toxicity  
Genotoxicity  To detect chemicals that induce genetic damage by various 
mechanisms  
Reproductive and 
developmental toxicity 
To reveal any effect of an active chemical on mammalian 
reproduction and development. 
Carcinogenicity  To examine carcinogen that is an agent directly involved in 
causing cancer.  
Immunotoxicology  To detect immune dysfunction resulting from exposure of 
an organism to a chemical  
Local tolerance  To ascertain whether chemicals are tolerated at site in the 
body.  
Safety pharmacology  To investigate the potential undesirable pharmacodynamic 
effects of a chemical on physiological functions in relation 
to exposure in the therapeutic range and above.  
Table 1. Non-clinical toxicology testing. Toxicological testing is conducted on large numbers 
of animals of different species in an attempt to predict adverse effects that might be 
triggered by the drug in humans. Genotoxicity assays are mandatory regulatory studies 
designed to detect potential mutagens and/or carcinogens. 
differ in their substrate specificities and the reactions catalyzed (Guengerich, 1997). Second, 
with phenobarbital/ 5,6-benzoflavone induction, although the expression levels of CYP1A 
and 2B enzymes are markedly elevated, others such as CYP3A are affected only in a minor 
way, whereas others (e.g., CYP2C11) may decrease (Guengerich et al., 1982). Third, the 
system is set up to favor CYP-mediated metabolism. Some phase II enzymes, such as UDP-
glucuronosyltransferases (UGT), glutathione S-transferases (GST), sulfotransferase (SULT), 
or N-acetyl transferases, are not active in the reduced form of the nicotinamide adenine 
 dinucleotide phosphate (NADPH)-supplemented S9 system (S9 mix) because other 
cofactors and additives (e.g., uridine diphosphate glucuronic acid, glutathione, acetyl-
coenzyme A, etc.) would be needed (Ku et al., 2007; Obach and Dobo, 2008). This can be 
essential not only for reducing potential false positives (e.g., reactive electrophiles that 
would be rapidly quenched by conjugation in vivo before being able to cause mutation) but 
also for false negatives because some conjugation reactions can yield metabolites that are 
more reactive than their substrate (e.g., sulfation of N-hydroxy-2-acetylaminofluorene or 
acetylation of N-hydroxylated heterocyclic amines) (Dashwood, 2002; Ku et al., 2007). The 
rat liver S9 mix may represent an incomplete picture of the metabolism that can occur in 
vivo (Fig. 2). 
To detect those genotoxic potential, some genotoxic metabolites have to be formed in the 
target cell by endogenous enzymes that are not represented in standard in vitro test systems. 
One of the major reasons is that certain types of active metabolites (including many   
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                         A. Rat liver S9 mix                             B. Human hepatocyte 
Fig. 2. Detection of genotoxicity using rat liver S9 mix compared to the expression of 
genotoxicity occurring hepatocyte. A. The detection method of genotoxicity is currently 
used a rat liver S9 fraction in the in vitro genotoxicity testing. B. The expression of 
genotoxicity is occurred in the hepatocyte. It can be questioned if the standard Aroclor-
induced rat liver S-9 fraction represents an appropriate surrogate for the metabolic 
capabilities of humans. However, in human hepatocyte, the genotoxicity was expressed 
through the comprehensive metabolic pathway including phase I and phase II drug-
metabolizing enzymes. Thus human hepatocyte can be a good genotoxicity test system 
reflecting human metabolism. In addition, human hepatocyte has complete metabolism 
consisting oxidation, reduction, hydrolysis and conjugation, whereas rat liver S9 mix is set 
up to favor CYP-mediated metabolism and the other enzymes present in the system that 
could be responsible for detoxification of reactive intermediates are not supplemented with 
the appropriate cofactors (e.g., UGT, GST, methyl transfereases, etc), thus potentially 
providing an unrealistic metabolic profile. 
short-life phase-2 metabolites) will not penetrate cell membranes sufficiently. If these types 
of metabolites are generated extracellularly, most in vitro genotoxicity testing showed 
negative results since the access to nuclear DNA was difficult. Another reason is that the 
diffusion pathways are longer for externally generated active metabolites resulting in more 
opportunities for alternative chemical reactions (e.g. with components of S9 or cell 
membranes) than for metabolites formed in the target cell. Electrophilic metabolites of a 
chemical bind to serum or S9 proteins (forming protein adducts) and this reduces the rate of 
binding to DNA to form DNA adducts. 
Therefore it is considered that the use of genetically engineered cells is the most reliable 
remedy to avoid the shortcomings of the extracellular metabolic activation systems such as 
human S9 and recombinant human CYPs (Fig. 3). To be useful tools for the prediction of 
drug metabolism and toxicity in the human liver, Yoshitomi et al. established a series of 
HepG2 transformants expressing the cytochromes 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 
2E1 and 3A4 with the apparent Vmax values for characteristic substrates (Table 2) in a 
previous work (Yoshitomi et al., 2001). Since most human drug metabolism is catalyzed by 
CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4, this HepG2 transformant system would be 
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more suitable for the genotoxic assessment of chemicals than the induced rat liver S9 
fraction in the routine screening when considering human hepatic metabolism in the future. 
Therefore in the present thesis, we explored the usefulness of a series of 10 transformants 
expressing major human CYP isoforms such as CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 
2D6, 2E1 and 3A4 in HepG2 cells established previously to assess the genotoxicity of 
metabolites (Fig.3) (Hashizume et al., 2009; Hashizume et al., 2010). 
 
Name of  Expressed Catalytic  Kinetic analysis 
transformant CYP 
isoform 
reaction measured Transformant
Km (μM) 
Human liver 
microsomes 
Km (μM)a 
Transformant 
Vmax 
(ρmol/min/mg) 
Hepc/1A1.4 CYP1A1 7-Ethoxyresorufin 
O-deethylation 
0.25 0.19 56 
Hepc/1A2.9 CYP1A2 7-Ethoxyresorufin 
O-deethylation 
0.72 0.39 2 
Hepc/2A6L.14 CYP2A6 Coumarin 7-
hydroxylation 
5.1 2.3 812 000 
Hepc/2B6.68 CYP2B6 7-Ethoxycoumarin 
O-deethylation 
81 – 80 000 
Hepc/2C8.46 CYP2C8 Taxol 6-
hydroxylation 
7.4 24 9400 
Hepc/2C9.1 CYP2C9 Tolbutamide 4-
hydroxylation 
45 120 25 000 
Hepc/2C19.12 CYP2C19 (S)-Mephenytoin 4'-
hydroxylation 
8.3 16 140 000 
Hepc/2D6.39 CYP2D6 Bufuralol 1'-
hydroxylation 
17 40 14 
Hepc/2E1.3-8 CYP2E1 p-Nitrophenol 
hydroxylation 
88 30 120 
Hepc/3A4.2-30 CYP3A4 Testosterone 6ǃ-
hydroxylation 
96 89 71 
Table 2. Characteristics of a series of 10 transformants expressing major human CYP 
isoforms such as CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4 in HepG2 cells 
(Yoshitomi et al., 2001). a). Iwata et al., 1998. 
2. Advantages of HepG2 transformants expressing a series of human CYP 
isoforms in the in vitro genotoxicity testing 
The need for metabolism, especially CYP-mediated one, for in vitro genotoxicity testing has 
been recognized for many years. Most target cells for genotoxicity assays lack sufficient CYP 
to activate many promutagens. Therefore, extracellular systems are commonly utilized to 
provide metabolism. The rat liver S9 fraction contains multiple CYPs and have been used 
with many target cell types in genotoxicity testing. However, this metabolic activation 
system suffers from certain limitations; (1) generation of reactive metabolites outside of the 
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target cell, (2) requirement of high exposure concentration to compensate for short exposure 
times and (3) differences in metabolism compared to intact tissues. To overcome these 
limitations, the use of genetically engineered stable cell lines expressing CYPs has studied. 
The liver is the tissue containing the greatest concentrations of drug-metabolizing enzymes, 
such as the CYP enzyme family, among many others. In human liver, about 70% of the total 
CYP could be accounted for by CYP1A2, 2A6, 2B6, 2C, 2D6, 2E1 and 3A proteins (Rendic 
and Guengerich, 1997). In the extrahepatic organs such as lungs and kidneys, CYP1A1 is 
present. CYPs catalyze to form toxic reactive intermediates from many chemicals. As it is 
well known that there are significant quantitative and qualitative differences between 
laboratory animals and humans in their CYP subtypes, it is necessary to use human CYP 
isoforms to predict the metabolism and toxicity of chemicals in humans. 
 
CYP1A2 CYP2B6
CYP2C9
CYP2C19
CYP2D6
CYP2E1
CYP3A4
CYP1A1
Cytosol
Microsomes
Nucleus
CYP
UGTNAT
SULTGST
Chemical
Phase I drug metabolizing enzymes
Oxidation Reduction Hydrolysis
Phase II drug metabolizing enzymes
Conjugation
Cytosol
Microsomes
Nucleus
CYP
UGTNAT
SULTGST
HepG2 (low CYP activity)
Phase I drug metabolizing enzymes
Oxidation Reduction Hydrolysis
Phase II drug metabolizing enzymes
Conjugation
Chemical
HepG2  transformants
expressing human CYP isoforms
 
Fig. 3. HepG2 transformants expressing human CYP isoforms relating drug metabolism. The 
pie chart shows the contribution of each CYP isoform to the human drug metabolism 
(Lewis, 2004). It has been concerned about the low CYP activities in HepG2 cells, so we 
established the HepG2 transformant system expressing a series of human CYP isoforms. 
In vitro systems, particularly those derived from liver, are a commonly applied tool to gain 
a better understanding of the metabolism of drugs and other xenobiotics. Also in 
genotoxicity, a number of publications are discussed which are relevant for the use of 
human derived liver cell lines. One of the most promising lines is the human HepG2 cell 
line, originally isolated by Aden et al. in 1972 from a primary hepatoblastoma of an 11-year-
old Argentine boy. This cell line retains many of the specialized functions normally lost by 
primary hepatocytes in culture such as secretion of the major plasma proteins. Since several 
publications alerted that HepG2 lacks a few drug-metabolizing enzymes such as CYP2E1 
and 1A2, transfectants constitutively expressing these enzymes have been constructed. 
Cederbaum and coworkers developed a line, which possesses CYP2E1 activity and used it 
in a number of mechanistic studies (for review see Kessova and Cederbaum, 2003). 
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In our previous study, Yoshitomi et al. has established a series of HepG2 transformants 
expressing the CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4 (Yoshitomi et al., 
2001). Since most human drug metabolism is catalyzed by CYP1A2, 2C8, 2C9, 2C19, 2D6, 
2E1 and P3A4, this HepG2 transformant system would be more suitable for the genotoxic 
assessment of chemicals than the induced rat liver S9 fraction in the routine screening when 
considering human hepatic metabolism in the future.  
Therefore, we examined the advantages of HepG2 transformants expressing a series of 
human CYP isoforms as a better alternative for metabolic activation system in the in vitro 
genotoxicity testing. In section 2.1, the sensitivity of this system to detect genotoxicity 
requiring CYP activation was confirmed in the in vitro micronucleus (MN) tests using well-
studied model chemicals. In section 2.2, this system allowed us to investigate the 
genotoxicity of model chemicals for which the contributing CYP isoforms, especially those 
mediated by CYP1A2 or 3A4 which is known to metabolize many drugs in humans, have 
not yet been identified. In section 2.3, the relevance of the interaction between phase I and 
phase II drug-metabolizing enzymes, e.g., UGT, GST, and SULT, in the test system was 
demonstrated in a MN test of tamoxifen or safrole, which has been reported to be 
metabolized by enzymes of both phases. 
2.1 Basic characteristics of the HepG2 transformants on genotoxic assessment and 
confirmation of their sensitivity with model chemicals requiring CYP activation 
HepG2 transformants were checked for their response to known chemicals in which the 
CYP isoforms responsible for which genotoxicity has been reported. As model chemicals, we 
selected BP, DMBA, CP and ifosfamide. In BP metabolism, CYP1A1 showed clearly the 
highest activity among the hepatic CYP isoforms reported (Fig. 4 A). Significant formation 
of some metabolites was also observed with CYP1A2 and 3A4 (Bauer et al., 1995). In the 
DMBA metabolism (Fig. 4 B), it had been shown that CYP1A1 had clearly the highest 
activity among the hepatic CYP isoforms (Shimada and Fujii-Kuriyama, 2004; Shou et al., 
1996) and that significant formation of some metabolites was also observed with CYP1A2, 
2B6 and 2C9 (Shou et al., 1996). CP is efficiently metabolized by CYP2B6, 2C9 and 3A4 (Jing 
et al., 2006, Chang et al., 1993)(Fig. 4 C). Ifosfamide had been demonstrated to be efficiently 
metabolized by CYP2B6 and 3A4 (Chang et al., 1993; Jing et al., 2006)(Fig. 4 D).  
Firstly, BP treatment produced MN induction in the transformants expressing CYP1A1, 
CYP1A2 and CYP3A4 (Fig. 5 A). These CYP isoforms were reported to be responsible for BP 
activation (Bauer et al., 1995). Secondly, MN induction by DMBA in a HepG2 transformant 
expressing CYP1A1 was significantly higher than those in HepG2 and Hepc-Mock cells (Fig. 
5 B). CYP1A1 is known to be the most active among the CYP isoforms to metabolize DMBA 
(Shou et al., 1996). Thirdly, CP treatment caused MN induction in the transformants 
expressing CYP1A2, 2B6, 2C9 and 3A4 (Fig. 5 C). CYP2B6, 2C9 and 3A4 are reported to be 
involved the metabolic activation of CP (Jing et al., 2006; Chang et al., 1993). Finally, in the 
treatment with ifosfamide, significant MN inductions were found in the transformants 
expressing CYP1A1, 2C9, 2C19, 2D6 and 3A4 (Fig. 5 D). Ifosfamide had been demonstrated 
to be efficiently metabolized by CYP2B6 and 3A4 (Chang et al., 1993; Jing et al., 2006). These 
results showed HepG2 transformants system have the appropriate sensitivity to detect 
genotoxicity requiring CYP activation tests using well-studied model chemicals. 
In addition, DMBA treatment unexpectedly produced MN induction in some transformants 
expressing CYP2C9, 2D6 and 3A4 (Fig. 4 B). However, it was reported that CYP2C9 was 
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capable of metabolizing DMBA while CYP2D6 and 3A4 exhibited relatively low metabolic 
activity to DMBA (Shou et al., 1996). Similarly, significant MN inductions by ifosfamide 
were found in the transformants expressing CYP1A1, 2C9, 2C19, 2D6 and 3A4 (Fig. 4 D). 
Ifosfamide is mainly metabolized by CYP2B6 and 3A4 (Chang et al., 1993; Jing et al., 2006). 
CYP1A1 and 2C19 are relatively minor CYP isoforms to DMBA metabolic activation, but the 
involvement in the genotoxicity of ifosfamide metabolite of these CYP isoforms were 
demonstrated in the present study (Fig. 4 D). 
 
A 
 
B 
 
C 
 
D 
 
Fig. 4. Metabolic activation pathway of BP (A), DMBA (B), CP (C) and ifosfamide (D). A). BP is 
mainly metabolized by CYP1A1 to produce the benzo(a)pyrene 7, 8-oxide. B). DMBA (7, 12-
DMBA) is mainly metabolized by CYP1A1 to produce the 7, 12-DMBA-3, 4-oxide. C). 
Cyclophosphamide (CP) is mainly metabolized by CYP2C9 and 3A4 to produce the 4-hydroxy 
cyclophosphamide. D). Ifosfamide is mainly metabolized by CYP2B6 and 3A4 to produce the 
4-hydroxy ifosfamide. 
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Fig. 5. Micronucleus induction of BP (A), DMBA (B), CP (C) and ifosfamide (D) by 
expression of CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4. A). The cells 
(1×105 cells) were seeded onto a 24-well plate for 24 h and then treated with 0.5% DMSO 
(heavy gray bars), 200 ng/ml (light gray bars) or 400 ng/ml (medium gray bars) BP. B). The 
cells (1×105 cells) were seeded onto a 24-well plate for 24 h and then treated with 0.5% 
DMSO (heavy gray bars), 78 ng/ml (light gray bars) or 156 ng/ml (medium bars) DMBA. 
C). The cells (1×105 cells) were seeded onto a 24-well plate for 24 h and then treated with 
0.5% saline (heavy gray bars), 1 mg/ml (light gray bars) or 2 mg/ml (medium gray bars) 
CP. D). The cells (1×105 cells) were seeded onto a 24-well plate for 24 h and then treated with 
0.5% saline (heavy gray bars), 500 μg/ml (light gray bars) or 1000 μg/ml (medium gray 
bars) ifosfamide. Values were normalized with the mean DMSO- or saline-treated control 
value of 3 experiments for each transformant. Each bar represents the mean ± S.D. Data 
were tested using Student’s t-test when the variance was homogeneous or Aspin & Welch t 
test when the variance was heterogeneous (*P<0.05, compared with Hepc-Mock). 
Based on the results in section 2.1, it was showed that genotoxic metabolites could be 
produced by not only the most active CYP isoform but also by other less active CYPs and 
that this transformant system could detect the genotoxic potential of chemicals requiring 
CYP activation not tested routinely in the early stage of drug development. 
One of major advantages of our system is the variety of human CYP isoforms. When 
considering replacement of the rat induced liver S9 fraction, increasing the number of the 
principal CYP isoforms would be desirable in order to cover the diverse CYP activities. As 
mentioned in the general introduction, our HepG2 system includes CYP1A1, 1A2, 2A6, 2B6, 
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2C8, 2C9, 2C19, 2D6, 2E1 and 3A4. Seven CYP isoforms (1A1, 1A2, 2C9, 2C19, 2D6, 2E1 and 
3A4) account for 95% of this activity and with 3A4 responsible for over 65% of the 
metabolism of current therapeutic agents. During phase I metabolism in humans, 90% of all 
drugs are oxidized by CYP isoforms with different substrate selectivities. Thus, our HepG2 
transformant system seems to cover most human drug metabolism mediated by human 
CYP isoforms but not by rat ones. Based on the results obtained in section 2.1, it was 
demonstrated that our HepG2 transformant system has an appropriate sensitivity for well-
studied chemicals which requires CYP activation for their genotoxicity.  
For assessing the genotoxicity of chemicals with human metabolism, our HepG2 
transformant system has more appropriate characteristics than other established cell lines 
used in toxicological testing and reviewed by Sawada and Kamataki (Sawada and 
Kamataki, 1998). Our HepG2 transformants are derived from hepatocyte that possesses 
other factors necessary for the function of CYP. Generally, the reactions catalyzed by CYP 
molecules require the presence of NADPH-CYP reductase and cytochrome b5 to support 
some CYP-mediated reactions. HepG2 has been shown to have NADPH-CYP reductase 
activity and cytochrome b5, although the levels are lower than those of human liver 
(Waxman et al., 1991; Patten et al., 1992). Therefore, our HepG2 transformant system does 
not need co-expression of reductase and/or cytochrome b5 with CYP enzymes. 
2.2 An exploration using HepG2 transformant to identify the CYP isoforms 
contributing to the genotoxicity by novel chemicals 
Given the multiplicity of CYP isoforms and the importance of other enzymes (hydrolases, 
transferase, etc.) in the metabolism of chemicals, there are two possible approaches to 
engineering cell lines. The introduction of single enzymes allows simple controlled 
mechanistic studies of the role of an individual enzyme in the metabolic activation of 
chemicals. Such system can also be viewed as the replacement of the laborious CYP 
purification/reconstitution analyses with a panel of engineered cells. However, to specify 
CYP isoform(s) involved in the activation of a certain chemical of unknown metabolism, a 
set of cell lines individually expressing the different CYP isoforms is needed. A series of 
HepG2 transformants expressing major 10 human CYP isoforms is a valuable tool, since 
most human hepatic drug metabolism is catalyzed by these expressing CYP isoforms. 
 
 
Fig. 6. Chemical structure and significant biological features of okadaic acid. This chemical is 
a shellfish poisoning toxin and known as a potent phosphatase 1 and 2A. This chemical was 
reported to be induced micronucleus in the presence of rat liver S9 mix (Hégarat et al., 2004). 
In this section, the following possibility was elucidated that the set of transformants can be 
used for screening for the genotoxicity of newly developed pharmaceutical candidates of 
unknown metabolism in human in vivo. As model chemicals, we selected okadaic acid (OA) 
and ǃ-endosulfan.  
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Hégarat et al. found that OA enhanced formation of MN in the presence of a metabolic 
activation system (Hégarat et al., 2004), although the CYP isoforms involved in the MN 
induction were not reported. Thus we selected OA as a model chemical to evaluate the 
ability of our system to investigate which CYP isoform is involved in producing unknown 
genotoxic metabolites.  
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Fig. 7. Micronucleus induction of OA. A). Micronucleus induction of OA by expression of 
CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4. The cells (1×105 cells) were 
seeded onto a 24-well plate for 24 h, and then treated with 0.5% DMSO (heavy gray bars), 5 
ng/ml (light gray bars) or 10 ng/ml (medium gray bars) OA. After 48 h, the cells were 
collected and sampled. One thousand interphase cells per each treatment were scored and 
the incidence of cells with micronuclei was calculated. Values were normalized with the 
mean DMSO-treated control value of 3 experiments in each transformant. Each bar 
represents the mean ± S.D. of 3 experiments. Data were tested using Student’s t-test 
(*P<0.05, compared with Hepc-Mock). B). Effects of furafylline, a CYP1A2 specific inhibitor 
for micronucleus induction by various chemicals in the transformant expressing CYP1A2. 
The cells (1×105 cells) were seeded onto a 24-well plate for 24 h, and then treated with 0.5% 
DMSO, 5 or 7.5 ng/ml OA, 400 ng/ml BP and 25 ng/ml MMC in the absence (heavy gray 
bars) or presence of 5 μM (lihgt gray bars) or 50 μM (medium gray bars) furafylline. Values 
were normalized with the mean DMSO-treated control value without an inhibition of three 
experiments in each transformant. Each bar represents the mean ± S.D. of 3 experiments. 
Data were tested using Student’s t-test (*P<0.05, compared with no inhibition). C). Effects of 
siRNA to CYP1A2 on micronucleus induction by OA in the transformant expressing 
CYP1A2. The cells (1×105 cells) were seeded onto a 24-well plate for 24 h in the presence of 
50 nM siRNA for non-targeting (heavy gray bars) or CYP1A2 (light gray bars). Medium was 
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changed with a fresh one containing 0.5% DMSO, 5 and 7.5 ng/ml OA. After 48 h, the cells 
were collected and sampled. Values were normalized with the mean DMSO-treated control 
value without siRNA of three experiments in each transformant. Each bar represents the 
mean ± S.D. of 3 experiments. Data were tested using Student’s t-test (*P<0.05, compared 
with non-targeting siRNA). D). Effects of external metabolic activation system for CYP1A2 
on micronucleus induction by okadaic acid in Hepc. The cells (1×105 cells) were seeded onto 
a 24-well plate for 24 h, and then treated with 0.5% DMSO, 5 or 7.5 ng/ml OA in the absence 
(heavy gray bars) or presence of Insect Cell Control SupersomesTM (light gray bars) or 
Human CYP1A2 SupersomesTM (medium gray bars). Values were normalized with the 
mean DMSO-treated control value without microsomes of 3 experiments in each 
transformant. Each bar represents the mean ± S.D. of 3 experiments. Data were tested using 
Student’s t-test (*P<0.05, compared with the control microsomes). 
OA significantly increased the fold induction of MN in the transformant expressing CYP1A2 
compared with that obtained in Hepc-Mock (Fig. 7 A). Furthermore, inhibitory effects of a 
specific inhibitor of CYP1A2 and siRNA to CYP1A2 on MN induction by OA were shown 
(Figs.7 B and 7 C, respectively). Moreover, co-treatment with OA and microsomes 
expressing CYP1A2 showed MN induction in Hepc-Mock cells (Fig. 7 D). These results 
indicated that MN induction by OA could be associated with the presence of CYP1A2 
activity, suggesting that CYP1A2 is involved in the genotoxic activation of OA. 
 
 
Fig. 8. Proposed metabolic pathway of ǃ-endosulfan. In mammalian systems, ǃ-endosulfan 
is metabolized to endosulfan sulfate, which is the most persistent metabolite, and also to 
endosulfan diol, which is further metabolized to endosulfan ether, hydroxyether, and 
lactone [WHO, 1999]. 
ǃ-Endosulfan, shown in Fig. 8, is also reported to induce MN in HepG2 cells, suggesting 
that CYP activation might be involved in the MN induction (Lu et al., 2000); however the 
contributing CYP isoform to induce MN has not yet been investigated, to the best of our 
knowledge. Therefore we examined whether a series of HepG2 transformants could identify 
the CYP isoform contributing to the MN induction by ǃ-endosulfan as a model chemical. 
ǃ-Endosulfan significantly increased the fold induction of MN in the transformant 
expressing CYP3A4 compared with that obtained with the transformant Mepc-Mock (Fig. 8 
A). Furthermore, inhibitory effects of a specific inhibitor of CYP3A4 and of siRNA to 
CYP3A4 on MN induction by ǃ-endosulfan were shown (Figs. 8 B and 8 C, respectively). 
The activity of CYP3A4 in the transformant using the luminogenic substrate demonstrated 
that these inhibitory conditions decreased the activity to approximately 10% compared to 
control level. These results indicated that MN induction by ǃ-endosulfan could be 
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associated with the presence of CYP3A4 activity and suggested that CYP3A4 is involved in 
producing the genotoxic metabolites of ǃ-endosulfan. 
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Fig. 9. Micronucleus induction of ǃ-endosulfan by CYP3A4-mediated activation. a). A 
micronucleus induction of ǃ-endosulfan by expression of CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 
2C19, 2D6, 2E1 and 3A4. The cells (1×105 cells) were seeded onto a 24-well plate for 24 h, and 
then treated with 0.5% DMSO (heavy gray bars), 6.25 μg/ml (light gray bars) or 12.5 μg/ml 
(medium gray bars) ǃ-endosulfan. b). Effects of ketoconazole, a CYP3A4 specific inhibitor 
for micronucleus induction by various chemicals in the transformant expressing CYP3A4. 
The cells (1×105 cells) were seeded onto a 24-well plate for 24 h, and then treated with 0.5% 
saline, 100 ng/ml mitomycin C, 1000 μg/ml cyclophosphamide, 0.5% DMSO, 6.25 or 12.5 
μg/ml ǃ-endosulfan in the absence (heavy gray bars) or presence (light gray bars) of 1 μM 
ketoconazole. c). Effects of siRNA to CYP3A4 on micronucleus induction by various 
chemicals in the transformant expressing CYP3A4. The cells (1×105 cells) were seeded onto a 
24-well plate for 8 h in absence (heavy gray bars) or the presence of 50 nM siRNA for 
Negative control (light gray bars) or CYP3A4 (medium gray bars). d). Micronucleus 
induction of endosulfan sulfate in Hepc-Mock, the transformant expressing an empty vector 
only. The cells (1×105 cells) were seeded onto a 24-well plate for 24 h and then treated with 
0.5% DMSO (heavy gray bars), 8 μg/ml, (light gray bars), 10 μg/ml (medium gray bars) or 
12.5 μg/ml (solid bars) endosulfan sulfate. Statistical analysis was done in the same 
procedure as Fig. E, except for the Student’s t- test (#P<0.05, compared with the DMSO-
treated control group) in Fig. F d). 
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Lee et al. reported that ǃ-endosulfan is metabolized by CYP3A4 based on the results in the 
study with CYP isoform-selective inhibitor in human liver microsomes and with the 
incubation study of cDNA-expressed enzymes (Lee et al., 2006). They have also reported 
that human liver microsome incubation of ǃ-endosulfan in the presence of NADPH resulted 
in the formation of endosulfan sulfate (Lee et al., 2006). Based on these reports, we examined 
the genotoxicity of endosulfan sulfate in the Hepc-Mock cells in order to investigate whether 
this sulfate is the metabolite that induces MN in the ǃ-endosulfan–treated transformant 
expressing CYP3A4. As shown in Fig. Fd, endosulfan sulfate induced MN with statistical 
significance at 12.5 μg/ml. This result demonstrated that endosulfan sulfate was the 
genotoxic metabolite and that this metabolite was formed by CYP3A4 in the transformant 
treated with ǃ-endosulfan. 
Based on the results obtained in the OA and ǃ-endosulfan treatments, it was clearly 
demonstrated that the HepG2 transformant system was able to identify the CYP isoform 
relating to the genotoxicity of chemical metabolite(s) and was useful to elucidate the 
genotoxicity of a new chemical or a drug candidate in the presence of the metabolic 
activation system. 
More effort as for CYP induction is necessary, but the results obtained in the present study 
demonstrated the availability of these transformants expressing human CYP to elucidate the 
genotoxic potential of the chemicals that require metabolic activation to create risk to 
humans. In order to validate these transformants, an additional study is in progress with 
more chemicals that have been well studied in the metabolic activation or inactivation by 
CYP enzymes. 
These results clearly demonstrated that the HepG2 transformant system was able to identify 
the CYP isoform related to the genotoxicity of chemical metabolite(s) and was useful to 
elucidate the genotoxicity of a new chemical or a drug candidate in the presence of the 
metabolic activation system. 
2.3 Genotoxic assessment of chemicals metabolized by phase I and phase II drug-
metabolizing enzymes 
As mentioned in the Introduction section, to detect chemicals which require bioactivation to 
electrophiles to exhibit a genotoxic and carcinogenic response, the standard in vitro 
genotoxicity testing also include incubation of the test chemicals with liver microsomal or S9 
fractions, as activation systems so that chemically stable xenobiotics can be converted to 
reactive electrophiles (Malling, 1971; Ames et al., 1973; Levin et al., 1984). However, it is 
possible that the Aroclor induced rat liver S9 system is not the most appropriate metabolite 
generation system for detecting drugs that may pose a carcinogenic hazard to humans. This 
is because the system is set up to favor CYP-mediated metabolism and the other enzymes 
present in the system that could be responsible for detoxication of reactive intermediates are 
not supplemented with the appropriate cofactors (e.g., UGT, GST, methyl transferases, etc), 
thus potentially providing an unrealistic metabolic profile. In a recent work by Obach and 
Dobo, it was revealed that many human in vivo metabolites arise via conjugation reactions 
with the limited 16 drugs (Obach and Dobo, 2008). This can be important not only for 
reducing potential false positives (e.g., reactive electrophiles that would be rapidly 
quenched by conjugation in vivo before being able to cause mutation) but can also be 
important for false negatives because some conjugation reactions can yield metabolites that 
are more reactive than their substrate (e.g., sulfation of aliphatic alcohols or glucuronidation 
of carboxylic acids; [Glatt et al., 1998; Sallustio et al., 2006]). 
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Fig. 10. Metabolic activation and inactivation pathways of tamoxifen. 
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Fig. 11. Micronucleus induction of tamoxifen by expression of CYP1A1, 1A2, 2A6, 2B6, 2C8, 
2C9, 2C19, 2D6, 2E1 and 3A4 (A), and effects of a phase II inhibitro on micronucleus 
indcution by tamoxifen (B). A). The cells (1×105 cells) were seeded onto a 24-well plate for 24 
h, and then treated with 0.5% DMSO (heavy gray bars), 1 μg/ml (light gray bars) or 2 μg/ml 
(medium gray bars) tamoxifen. No statistically significant increase was observed when 
compared with both Hepc-Mock and HepG2. B). The transformant cells expressing CYP3A4 
(1×105 cells) were seeded onto a 24-well plate for 24 h, and then treated with 0.5% DMSO 
(heavy gray bars), 2 μg/ml (light gray bars) or 3 μg/ml (medium gray bars) tamoxifen in the 
absence or presence of 50 μM diclofenac, a UGT inhibitor. 
In order to evaluate the relevance of the interaction between phase I and phase II drug-
metabolizing enzymes in the test system, the transformants were treated with tamoxifen as 
shown in Fig. 10. Tamoxifen is reported to be metabolized by CYP3A4 to ǂ-
hydroxytamoxifen and further metabolized by SULT to ǂ-hydroxytamoxifen sulfate ester as 
the putative reactive intermediate (Brown, 2009; White, 2003; Zhao et al., 2009). This 
intermediate reacts with the exocyclic amino group of guanines (the major reaction) and 
adenines (a minor reaction) in DNA (Osborne et al., 1996). UGT plays a detoxification role 
through the glucuronidation of ǂ-hydroxytamoxifen (Brown, 2009; White, 2003; Zhao et al., 
2009).  
As shown in Fig. 11 A, tamoxifen did not significantly induce MN at any concentration 
tested in any transformant. At much higher concentrations of each chemical, the frequencies 
of the micronuclei were decreased (data not shown), suggesting that the tested 
concentrations were appropriate to evaluate MN induction. Then to investigate the 
involvement of the detoxification pathway by UGT in the metabolism of tamoxifen, we 
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tested the effect of UGT inhibitor on the MN induction by tamoxifen. A small but significant 
increase in MN by tamoxifen was observed in the presence of the UGT inhibitor, diclofenac, 
in the transformants expressing CYP3A4 which contribute to the metabolic activation of 
tamoxifen to ǂ-hydroxytamoxifen (Fig. 11 B). This result indicated that the CYP3A4-
metabolite, ǂ-hydroxy-tamoxifen, was further metabolized by UGT to a genotoxically 
inactive substance. 
Another example is safrole. Safrole is reported to be hydroxylated predominantly by 
CYP2A6, 2C9, 2D6 or 2E1 and further metabolized by SULT to 1’-sulfooxysafrole (Andrew 
and Brian, 2007; Rietjens et al., 2005)(Fig. 12). This intermediate forms the electrophilic 
carbocation of safrole, suggesting the production of DNA adduct (Rietjens et al., 2005). On 
the other hand, the safrole-2’, 3’-oxide formed from the parent safrole by epoxide hydrolases 
or 1’-hydroxysafrole-2’, 3’-oxide from 1’-hydroxysaforle are reported to be detoxified by 
GST (Rietjens et al., 2005).  
As shown in Fig. 13 A, safrole did not significantly induce MN at any concentration tested in 
any transformant. At much higher concentrations of each chemical, the frequencies of the 
micronuclei were decreased (data not shown), suggesting that the tested concentrations 
were appropriate to evaluate MN induction. Then to investigate the involvement of the 
detoxification pathway by GST in the metabolism of safrole, we tested the effect of GST 
inhibitor on the MN induction by safrole. Significant increases were seen in the presence of 
the GST inhibitor, ethacrynic acid, in the transformants expressing CYP2D6 responsible for 
the genotoxic activation of safrole to 1’-hydroxysafrole (Fig. 13 B). This result suggested that 
CYP2D6-mediated metabolite, 1’-hydroxysafrole, was further metabolized by GST not 
exerting its genotoxicity in the metabolic pathway. 
 
 
Fig. 12. Metabolic activation and inactivation pathways of safrole. 
The results for tamoxifen and safrole clearly demonstrated that interaction between the 
phase I and II drug-metabolizing enzymes was crucial to assess the genotoxicity of 
chemicals in the presence of a metabolic activation system. The interplay between the phase 
I and II enzymes is lacking in the NADPH-supplemented rat liver S9 system due to an 
absence of co-factor necessary for several phase II enzymes such as UGT or GST. 
Furthermore, the reactive intermediates have to be formed in the target cell because some 
conjugates have poor membrane permeability. These results raise the possibility that the 
induced rat liver S9 system may generate mutagenic metabolites of no relevance, or worse 
even may not generate a mutagenic metabolite that would be generated by human enzymes. 
Therefore, a set of HepG2 transformants is a superior test system for mimicking the 
metabolism occurring in the human liver and the use of this system can potentially provide 
more relevant data than current genotoxicity tests. 
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Drug metabolism is generally regarded as proceeding via 2 stages, phase I and phase II. The 
induced rat liver S9 fraction as an exogenous metabolic activation system is supplemented 
with only NADPH for CYP-mediated metabolism. The appropriate cofactors for phase II 
drug-metabolizing enzymes (e.g. UGT, GST, SULT and NAT) are absent. This means these 
phase II enzymes are not active in the rat liver S9 fraction and that this leads not only for 
potential false positives (e.g., reactive electrophiles that would be rapidly quenched by 
conjugation in vivo before being able to cause mutation) but also for false negatives because 
some conjugation reactions can yield metabolites that are more reactive than their substrate 
(Dashwood, 2002; Ku et al., 2007). In other words, the use of an S9 system with NADPH 
may represent an incomplete picture of the metabolism that can occur in vivo. In particular, 
it is well-studied that SULTs are able to sequester some proximate mutagens through the 
 
 
A     B 
Fig. 13. Micronucleus induction of safrole by expression of CYP1A1, 1A2, 2A6, 2B6, 2C8, 
2C9, 2C19, 2D6, 2E1 and 3A4 (a), and effects of a phase II inhibitro on micronucleus 
indcution by safrole (b). a). The cells (1×105 cells) were seeded onto a 24-well plate for 24 h, 
and then treated with 0.5% DMSO (heavy gray bars), 83.3 μg/ml (light gray bars) or 125 
μg/ml (medium gray bars) safrole. No statistically significant increase was observed when 
compared with both Hepc-Mock and HepG2. b). The transformant cells expressing CYP2D6 
(1×105 cells) were seeded onto a 24-well plate for 24 h and then treated with 0.5% DMSO 
(heavy gray bars), 41.7 μg/ml (light gray bars), 62.5 μg/ml (medium gray bars) or 83.3 
μg/ml (solid bars) safrole in the absence or presence of 15 μM ethacrynic acid, a GST 
inhibitor. 
transfer of a sulfuryl group. However are these are also not active in the standard testing 
system because the necessary cofactor, 3’-phosphoadenosine-5’-phosphosulfate, is not 
added (Glatt, 2000; Glatt, 2005). From the study by Obach and Dobo using 16 drugs 
commonly used, not all metabolites observed as significant in humans in vivo are generated 
in the system using rat or human S9 fractions (Obach and Dobo, 2008).. Furthermore, they 
reported that a metabolite observed in humans in vivo was only seen in the rat S9 system 
and not the human S9 system in a few cases, (Obach and Dobo, 2008). Many human in vivo 
metabolites arise via conjugation reactions, which will not be observed in the in vitro S9 
system as presently supplemented in standard in vitro genotoxicity tests. In addition, with 
regard to similarity to in vivo metabolite profiles, the results of the in vitro testing presented 
in the literature by Obach and Dobo clearly demonstrate a limitation of both systems, in that 
both human and rat S9 predominantly generate metabolites that are the result of one to two 
metabolic reactions (>90%). 
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The induced rat liver S9 fraction has another limitation. To be detected as mutagens, some 
genotoxic metabolites have to be formed within the target cell by enzymes that are not 
represented in standard in vitro test systems. SULT-dependent activations are not uncommon. 
Using genetically modified target cells, activation by SULTs has been demonstrated for more 
than 100 chemicals, including various carcinogens (such as tamoxifen, cyproterone acetate, 
safrole, nitrofen and some nitrotoluenes) that are missed in conventional test systems (Glatt 
2000, Glatt 2005, Glatt and Meinl, 2005). Depending on the compound, varying SULT forms 
were required for the activation. Like N-sulfooxy-2-acetylaminofluorene, several other sulfo 
conjugates [e.g. furfuryl sulfate and 1-(L-sulfooxyethyl) pyrene] had to be formed within the 
target for a positive test result. Other reactive sulfo conjugates undergo spontaneous 
substitution reactions with components of the culture medium, such as chloride anions, 
leading to the formation of secondary, membrane-penetrating active species (Glatt et al., 1990). 
Moreover, cDNA-mediated expression of organic anion transporters in target cells enhanced 
the genotoxic effects of some reactive sulfuric acid esters externally added (Bakhiya et al., 
2006). Such uptake mechanisms might play a role in the organotropism of reactive species, but 
should not be relied on when testing new compounds.  
Other conjugating enzymes (some UGTs, GSTs and NATs) have also been expressed in 
target cells. The activation of promutagens by UGTs in such models has not yet been 
reported (and not been studied). However, co-expression of human UGT1A1 provided 
protection against the mutagenicity and cytotoxicity of PhIP in CHO-derived cells 
engineered for expression of CYP1A2 (Malfatti et al., 2005). Human GST T1, expressed in 
Salmonella typhimurium, strongly enhanced the mutagenicity of various dihalogenated 
alkanes as well as diepoxybutane (Thier et al., 1996). The activation of some of these agents 
could also be demonstrated using external GSH-conjugating systems (Rannug et al., 1978), 
but the extent of the uptake and its dependence on the structures of the reactive GSH 
conjugates are largely unexplored. Heterologous expression of GSTs in mammalian cells 
conferred resistance against various alkylating agents; in some cases, this protection was 
enhanced by, or was even strictly dependent on, the co-expression of an export pump (MRP-
1 or MRP-2) (Smitherman et al., 2004). The expression of endogenous acetyltransferases in 
Salmonella may be a reason for the high mutagenic activity observed in the Ames test with 
many amino- and nitro-arenes, whose final activation step is often an O-acetylation. 
Salmonella strains are available in which O-acetyltransferase has been replaced by a 
mammalian NAT (Glatt and Meinl 2005, Grant et al., 1992), which differ in substrate 
specificity. Thus, various aromatic hydroxamic acids are activated to mutagens by human 
NATs, but not by OAT. Such differences may often lead to misleading results when the 
standard bacterial strains are used. Unlike typical phase II metabolites, acetyl conjugates are 
uncharged. Nevertheless the site of their formation can strongly affect the outcome of 
mutagenicity experiments. Thus, PhIP shows much higher mutagenicity in S. typhimurium 
TA98 compared to an O-acetyltransferase-deficient variant of this strain; however, purified 
O-acetyltransferase in the presence of its cofactor acetyl-CoA had drastically reduced its 
bacterial mutagenicity (although it strongly enhanced the covalent binding to naked DNA) 
(Saito et al., 1985). Various standard mammalian target cells, including most sublines of V79 
cells, do not express any endogenous NAT. Heterologous expression of human NATs in 
these cells strongly enhanced the genotoxic effects of many amino- and nitro-arenes (Glatt, 
2005; Glatt, 2006). For example, induction of gene mutations by 3-nitrobenzanthrone 
required 100 times lower substrate concentrations in NAT2-expressing compared to control 
V79 cells. The isomer, 2-nitrobenzanthrone, was mutagenic in cells engineered for 
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expression of human SULT1A1, but not in control cells. 2-Amino-3-methylimidazo[4,5-f]- 
quinoline induced gene mutations in V79 cells co-expressing human NAT2 or NAT1 
together with human CYP1A2, even at a concentration of 0.01 and 1 μM, respectively, but 
was inactive (even at 30 μM) in cells expressing only CYP1A2 (Glatt, 2005; Glatt, 2006).  
Genotoxicity is a branch of the field of toxicology that assesses the effects of chemicals on 
DNA or genetic processes of living cells. Such effects can be accessed directly by measuring 
the interaction of chemicals with DNA or more indirectly through the production of gene 
mutation or chromosome alterations. The observations of these consequences in the 
genotoxicity tests suggest the carcinogenic concern of a chemical. Thus it is important to 
improve the genotoxicity test system to evaluate accurately based on the in vivo situation in 
human as much as possible. In the present research, I tried to imitate human metabolism by 
using human hepatocyte cell line expressing human CYP enzymes. My results indicated that 
metabolism focused only on CYP was not sufficient to evaluate the genotoxicity of the 
chemicals such as tamoxifen and safrole. A comprehensive metabolic pathway not only by 
phase I drug-metabolizing enzymes but also by phase II enzymes would be needed for the 
accurate assessment of genotoxicity. Moreover, other cellular defense systems (i.e., 
antioxidant system, GSH or ascorbic acid, and DNA repair system) are involved in the 
expression of genotoxicity by a chemical. Despite the proof that most chemical carcinogens 
undergo metabolic conversion into DNA-reactive intermediates, some compounds do not 
bind to DNA and are not mutagenic, yet they are carcinogenic in animal models and 
possibly also in humans. These non-genotoxic mechanisms such as induction of 
inflammation, immunosuppression, formation of reactive oxygen species, activation of 
receptors such as arylhydrocarbon receptor or estrogen receptor, and epigenetic silencing. 
Therefore ,another approach based on the non-genotoxic mechanism is necessary to predict 
the carcinogenic action from a certain chemical. Together, these genotoxic and non-
genotoxic mechanisms can alter signal-transduction pathways that finally result in 
hypermutability, genomic instability, loss of proliferation control, and resistance to 
apoptosis — some of the characteristic features of cancer cells. In this regard, we need to 
learn much more about the role and interplay of susceptibility and resistance function 
targeted by human carcinogens or involved in modulating human responses to carcinogenic 
chemicals. 
3. Future considerations 
Genotoxicity is a branch of the field of toxicology that assesses the effects of chemicals on 
DNA or genetic processes of living cells. Such effects can be accessed directly by measuring 
the interaction of chemicals with DNA or more indirectly through the production of gene 
mutation or chromosome alterations. The observations of these consequences in the 
genotoxicity tests suggest the carcinogenic concern of a chemical. Thus it is important to 
improve the genotoxicity test system to evaluate accurately based on the in vivo situation in 
human as much as possible. In the present research, I tried to imitate human metabolism by 
using human hepatocyte cell line expressing human CYP enzymes. My results indicated that 
metabolism focused only on CYP was not sufficient to evaluate the genotoxicity of the 
chemicals such as tamoxifen and safrole. A comprehensive metabolic pathway not only by 
phase I drug-metabolizing enzymes but also by phase II enzymes would be needed for the 
accurate assessment of genotoxicity. Moreover, other cellular defense systems (i.e., 
antioxidant system, GSH or ascorbic acid, and DNA repair system) are involved in the 
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expression of genotoxicity by a chemical. Despite the proof that most chemical carcinogens 
undergo metabolic conversion into DNA-reactive intermediates, some compounds do not 
bind to DNA and are not mutagenic, yet they are carcinogenic in animal models and 
possibly also in humans. These non-genotoxic mechanisms such as induction of 
inflammation, immunosuppression, formation of reactive oxygen species, activation of 
receptors such as arylhydrocarbon receptor or estrogen receptor, and epigenetic silencing. 
Therefore ,another approach based on the non-genotoxic mechanism is necessary to predict 
the carcinogenic action from a certain chemical. Together, these genotoxic and non-
genotoxic mechanisms can alter signal-transduction pathways that finally result in 
hypermutability, genomic instability, loss of proliferation control, and resistance to 
apoptosis — some of the characteristic features of cancer cells. In this regard, we need to 
learn much more about the role and interplay of susceptibility and resistance function 
targeted by human carcinogens or involved in modulating human responses to carcinogenic 
chemicals. 
4. Summary and conclusion 
Many carcinogens are known to be procarcinogens and require metabolic activation to exert 
their genotoxicity through the formation of reactive intermediates. Therefore, for hazard 
identification on the genotoxic potential of drug candidate and its metabolites, S9 fraction 
prepared from the livers of rats pretreated with phenobarbital and 5,6-benzoflavone or with 
Aroclor 1254 to induce drug-metabolizing enzyme activity must be used in the in vitro 
genotoxicity testing. However, it is frequently questioned as to whether such an in vitro 
metabolite generation system is the most relevant for human risk, or whether the assay would 
be better served by using a human-derived in vitro system. In the present study, we examined 
the advantages of HepG2 transformants expressing a series of human CYP isoforms as a better 
alternative for metabolic activation system in the in vitro genotoxicity testing.  
In section 2.1, the sensitivity of this system to detect genotoxicity requiring CYP activation 
was confirmed in the in vitro micronucleus tests using well-studied model chemicals. These 
results showed HepG2 transformants system have the appropriate sensitivity to detect 
genotoxicity requiring CYP activation tests using well-studied model chemicals. In addition, 
based on results obtained in the DMBA and ifosfamide treatments, HepG2 transformant 
system showed that genotoxic metabolites would be produced by not only the most active 
CYP isoform but also by other less active CYPs. 
In chapter 2.2, this system allowed us to investigate the genotoxicity of model chemicals for 
which the contributing CYP isoforms, especially those mediated by CYP1A2 or 3A4 which is 
known to metabolize many drugs in humans, have not yet been identified. Based on the 
results obtained in the okadaic acid and ǃ-endosulfan treatments, it was clearly 
demonstrated that the HepG2 transformant system was able to identify the CYP isoform 
relating to the genotoxicity of chemical metabolite(s) and was useful to elucidate the 
genotoxicity of a new chemical or a drug candidate in the presence of the metabolic 
activation system. 
In chapter 2.3, the relevance of the interaction between phase I and phase II drug-
metabolizing enzymes, e.g., UGT, GST, and SULT, in the test system was demonstrated in a 
MN test of tamoxifen or safrole, which has been reported to be metabolized by enzymes of 
both phases. Based on the results for tamoxifen and safrole, it was clearly demonstrated that 
the interaction between the phase I and phase II drug-metabolizing enzymes was crucial to 
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assess the genotoxicity of chemicals in the presence of a metabolic activation system. 
Therefore, a set of HepG2 transformants is a superior test system for mimicking the 
metabolism occurring in the human liver and the use of this system can potentially provide 
more relevant data than current genotoxicity tests. 
In conclusion, we have demonstrated the benefits of a newly established HepG2 
transformants expressing a series of human CYP isoforms for in vitro genotoxicity testing 
that reflects the comprehensive metabolic pathways including not only human CYP 
isoforms but also the phase II drug-metabolizing enzymes. 
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